Oddity Tech Ltd. Q2 2026 Earnings Call Summary

Strategic Performance and Operational Context

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributes the 25% revenue decline primarily to a technical 'algorithm dislocation' with its largest advertising partner, causing an audience drift that sharply increased customer acquisition costs (CPA) for IL MAKIAGE.

The company is prioritizing technical remediation over immediate growth for IL MAKIAGE, shifting resources toward intensive testing to retrain the ad algorithm rather than executing its planned product pipeline.

SpoiledChild is demonstrating operational resilience, on track for $350 million in 2026 revenue by maintaining strong unit economics and 12-month net revenue repeat rates exceeding 100% despite broader platform headwinds.

The launch of METHODIQ signals a strategic pivot toward the 'beauty and medicine' convergence, leveraging computer vision and ODDITY Labs' patented molecules to capture higher-intent medical-grade customers.

Management believes the current technical challenges are isolated to acquisition channels and do not reflect a lack of brand runway, citing stable trends in non-correlated business segments.

Strategic positioning is shifting toward a multi-brand platform to reduce dependency on any single brand or acquisition channel, The company is working to increase its distribution and channels to make the business more resilient, though it has no specific announcements to make yet, and aims for IL MAKIAGE to return to growth by 2027.

Strategic Outlook and 2027 Growth Framework

The 2027 strategy for IL MAKIAGE focuses on a return to growth supported by a deferred pipeline of new products, Management targets a return to growth for IL MAKIAGE in 2027, supported by a pipeline of new products ready to launch once acquisition costs recover.

METHODIQ is expected to exceed SpoiledChild's first-year revenue performance, with 2027 expansion plans targeting high-demand categories like longevity, metabolic health, and injectable peptide therapies.

Management plans to launch 'BRAND 4' in 2027, further diversifying the portfolio and leveraging the company's existing prescription and pharmacy fulfillment infrastructure.

Guidance for the remainder of 2026 assumes sequential improvement in revenue trends as the compounding impact of lost repeat sales from early-year acquisition gaps begins to stabilize.

Future gross margin targets remain in the high 60s, with management expecting recovery as they resume AOV optimization efforts that were paused during the current dislocation period.